159 related articles for article (PubMed ID: 10189263)
1. Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole.
Khoo SM; Porter JH; Edwards GA; Charman WN
J Pharm Sci; 1998 Dec; 87(12):1538-41. PubMed ID: 10189263
[TBL] [Abstract][Full Text] [Related]
2. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine.
Khoo SM; Edwards GA; Porter CJ; Charman WN
J Pharm Sci; 2001 Oct; 90(10):1599-607. PubMed ID: 11745718
[TBL] [Abstract][Full Text] [Related]
3. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state.
Humberstone AJ; Porter CJ; Edwards GA; Charman WN
J Pharm Sci; 1998 Aug; 87(8):936-42. PubMed ID: 9687337
[TBL] [Abstract][Full Text] [Related]
4. Effect of selected antimalarial drugs and inhibitors of cytochrome P-450 3A4 on halofantrine metabolism by human liver microsomes.
Baune B; Furlan V; Taburet AM; Farinotti R
Drug Metab Dispos; 1999 May; 27(5):565-8. PubMed ID: 10220483
[TBL] [Abstract][Full Text] [Related]
5. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine.
Humberstone AJ; Porter CJ; Charman WN
J Pharm Sci; 1996 May; 85(5):525-9. PubMed ID: 8742945
[TBL] [Abstract][Full Text] [Related]
6. Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5.
Baune B; Flinois JP; Furlan V; Gimenez F; Taburet AM; Becquemont L; Farinotti R
J Pharm Pharmacol; 1999 Apr; 51(4):419-26. PubMed ID: 10385214
[TBL] [Abstract][Full Text] [Related]
7. A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs.
Khoo SM; Prankerd RJ; Edwards GA; Porter CJ; Charman WN
J Pharm Sci; 2002 Mar; 91(3):647-59. PubMed ID: 11920750
[TBL] [Abstract][Full Text] [Related]
8. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.
Halliday RC; Jones BC; Smith DA; Kitteringham NR; Park BK
Br J Clin Pharmacol; 1995 Oct; 40(4):369-78. PubMed ID: 8554939
[TBL] [Abstract][Full Text] [Related]
9. Effects of prior administration of amodiaquine on the disposition of halofantrine in healthy volunteers.
Omoruyi SI; Onyeji CO; Daniyan MO
Ther Drug Monit; 2007 Apr; 29(2):203-6. PubMed ID: 17417075
[TBL] [Abstract][Full Text] [Related]
10. Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate.
Aideloje SO; Onyeji CO; Ugwu NC
Eur J Pharm Biopharm; 1998 Nov; 46(3):299-303. PubMed ID: 9885302
[TBL] [Abstract][Full Text] [Related]
11. Ion-pair reversed-phase high-performance liquid chromatographic analysis of halofantrine and desbutylhalofantrine in human plasma.
Onyeji CO; Aideloje SO
Ther Drug Monit; 1997 Dec; 19(6):682-7. PubMed ID: 9421111
[TBL] [Abstract][Full Text] [Related]
12. Effect of fluconazole on the pharmacokinetics of halofantrine in healthy volunteers.
Babalola CP; Kolade YT; Olaniyi AA; Adedapo A; Scriba GK
J Clin Pharm Ther; 2009 Dec; 34(6):677-82. PubMed ID: 20175801
[TBL] [Abstract][Full Text] [Related]
13. Ketoconazole-induced hepatic phospholipidosis in the mouse and its association with de-N-acetyl ketoconazole.
Whitehouse LW; Menzies A; Mueller R; Pontefract R
Toxicology; 1994; 94(1-3):81-95. PubMed ID: 7801332
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of halofantrine in man: effects of food and dose size.
Milton KA; Edwards G; Ward SA; Orme ML; Breckenridge AM
Br J Clin Pharmacol; 1989 Jul; 28(1):71-7. PubMed ID: 2775616
[TBL] [Abstract][Full Text] [Related]
15. Differences in the lipoprotein binding profile of halofantrine in fed and fasted human or beagle plasma are dictated by the respective masses of core apolar lipoprotein lipid.
McIntosh MP; Porter CJ; Wasan KM; Ramaswamy M; Charman WN
J Pharm Sci; 1999 Mar; 88(3):378-84. PubMed ID: 10052998
[TBL] [Abstract][Full Text] [Related]
16. Desbutylhalofantrine: evaluation of QT prolongation and other cardiovascular effects after intravenous administration in vivo.
McIntosh MP; Batey AJ; Porter CJ; Charman WN; Coker SJ
J Cardiovasc Pharmacol; 2003 Mar; 41(3):406-13. PubMed ID: 12605019
[TBL] [Abstract][Full Text] [Related]
17. The stereoselective metabolism of halofantrine to desbutylhalofantrine in the rat: evidence of tissue-specific enantioselectivity in microsomal metabolism.
Gharavi N; Sattari S; Shayeganpour A; El-Kadi AO; Brocks DR
Chirality; 2007 Jan; 19(1):22-33. PubMed ID: 17089336
[TBL] [Abstract][Full Text] [Related]
18. Direct determination of the enantiomers of the antimalarial drug halofantrine and its active metabolite N-desbutylhalofantrine in human plasma.
Terefe H; Blaschke G
J Chromatogr B Biomed Appl; 1994 Jul; 657(1):238-42. PubMed ID: 7952076
[TBL] [Abstract][Full Text] [Related]
19. Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine.
Kolade YT; Babalola CP; Olaniyi AA; Scriba GK
Eur J Clin Pharmacol; 2008 Jan; 64(1):77-81. PubMed ID: 17952423
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and elimination of quinine in healthy volunteers.
Mirghani RA; Hellgren U; Bertilsson L; Gustafsson LL; Ericsson O
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):423-7. PubMed ID: 12920491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
